Project Image:
Title of the project:
There is now increased understanding of the variability of effectiveness of non-pharmaceutical interventions (NPIs) in reducing the spread of SARS-CoV-2 over regions, social parameters and phases of the pandemic. However, the mid- and long-term effects of these NPIs remain poorly understood.
Project leader:
Dr. Nicole Schneiderhan-Marra
Project funding:
  • BMBF
Funding reference number:

Mid- and longterm effects of non-pharmaceutical interventions used during the COVID-19 pandemic on respiratory infections like respiratory syncitial virus, influenza and pneumococcal disease remain poorly understood but are crucial in the assessment of overall disease burden after NPIs. RESPINOW aims to develop an integrated model for simulation of transmission of several respiratory infections and collateral effects of NPIs on their disease burden in the mid- and long term. To aid the development of novel models on the spread of respiratory diseases mid- and long term post NPIs, a population-based cohort will be analysed for their immunity towards RSV and Influenza as well as post-pandemic contact behaviour in the coming years. For this purpose, the Multiplex Immunoassays Group at the NMI will further develop antibody tests against RSV and Influenza to generate seroprevalence data on their spread through the population.

Project partners:
  • Helmholtz Institute for Infection Research (HZI), Univ. Heidelberg, Max-Planck Institut für Dynamik und Selbstorganisation, KIT, Univ. Halle, TU Kaiserslauten, Univ. Münster, Univ. Köln and Robert-Koch-Institut